CureVac N.V.
DelistedCIK 1809122fmd_1YGPM4W3MGG093V691MCWDFD62Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Jun 30, 2025, 22 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|
| Total revenues | 13 | 17 | 49 | 103 | 67 | 54 | 535 |
| Cost of revenue | 18 | 28 | 14 | 238 | 184 | 124 | 106 |
| Gross profit | (5) | (11) | 35 | (135) | (117) | (71) | 429 |
| Research and development | 42 | 43 | 114 | 816 | 63 | 116 | 153 |
| Selling, general and administrative | 26 | 51 | 54 | 102 | 107 | 96 | 74 |
| Operating income | (73) | (99) | (110) | (412) | (249) | (274) | 178 |
| Interest expense | 0 | 1 | 22 | 10 | 4 | 2 | 1 |
| Income before taxes | (71) | (100) | (130) | (412) | (249) | (260) | 191 |
| Income tax expense | 0 | (0) | (1) | (1) | (0) | 0 | 29 |
| Net income from continuing operations | (71) | (100) | (129) | (412) | (249) | (260) | 162 |
| Net income | (71) | (100) | (129) | (412) | (249) | (260) | 162 |